Iranian Journal of Nuclear Medicine

Iranian Journal of Nuclear Medicine

Hot-clot artifact in lung parenchyma on [68Ga]Ga-PSMA-11 PET/CT can mimic prostate cancer metastasis

Document Type : Case Report

Authors
Nasim Norouzbeigi 1
Amir Reza Khorasanchi 1
Habibollah Dadgar 1
Atena Aghaee 2
1 Razavi Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, Iran
2 Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
10.22034/irjnm.2023.40091
Abstract
[68Ga]Ga-PSMA-11 PET/CT scan is an important whole-body imaging tool in oncology and is specifically used for staging and re-staging of prostate cancer, in recent years. Findings of significant focal accumulation of PSMA in the lung parenchyma without corresponding CT abnormalities are challenging and may be a cause for false positive interpretation of metastasis, caused by pulmonary microembolism due to hot-clot artifacts, as previously described in 2-[18F]FDG PET/CT studies. Here we present an unusual case of focal PSMA uptake in lung parenchyma without structural lesions on CT scan, which we believe is due to hot clot because of faulty injection techniques.
Keywords
PSMA PET/CT
Microembolism
Prostate cancer
Lung parenchyma
Subjects
  1. Stoykow C, Huber-Schumacher S, Almanasreh N, Jilg C, Ruf J. Strong PSMA Radioligand uptake by rectal carcinoma: who put the “S” in PSMA? Clin Nucl Med. 2017;42:225–6.
  2. Malik D, Kumar R, Mittal BR, Singh H, Bhattacharya A, Singh SK. 68Ga-labeled PSMA uptake in nonprostatic malignancies: has the time come to remove “PS” from PSMA? Clin Nucl Med. 2018;43:529–32.
  3. Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D, Bolton D, Hofman MS, Lawrentschuk N, Murphy DG. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol Open Sci. 2020 Apr 1;77(4):403-17.
  4. Backhaus P, Noto B, Avramovic N, Grubert LS, Huss S, Bögemann M, Stegger L, Weckesser M, Schaefers M, Rahbar K. Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives. Eur J Nucl Med Mol Imaging. 2018;45:860–77.
  5. Demirci E, Sahin OE, Ocak M, Akovali B, Nematyazar J, Kabasakal L. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging. Nucl Med Commun. 2016;37:1169–79.
  6. Prasad V, Steffen IG, Diederichs G, Makowski MR, Wust P, Brenner W. Biodistribution of [68Ga] PSMA-HBED-CC in patients with prostate cancer: characterization of uptake in Normal organs and tumour lesions. Mol Imaging Biol. 2016;18:428–36.
  7. Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–88.
  8. Karantanis D, Subramaniam RM, Mullan BP, Peller PJ, Wiseman GA. Focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of CT abnormality in PET/CT. J Comput Assist Tomogr 2007;31:800-805
  9. Abouzied MM, Crawford ES, Nabi HA. 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol 2005;33:145-155; quiz 162- 163
  10. Ha JM, Jeong SY, Seo YS, Kwon SY, Chong A, Oh JR, Song HC, Bom HS, Min JJ. Incidental focal  2-[ 18F]FDG accumulation in lung parenchyma without abnormal CT findings. Ann Nucl Med 2009;23:599-603